^
BIOMARKER:

IDH1 mutation

i
Other names: HEL-216, HEL-S-26, Epididymis Luminal Protein 216, Isocitrate Dehydrogenase 1 (NADP+), Epididymis Secretory Protein Li 26, IDH1, Isocitrate Dehydrogenase (NADP(+)) 1, Isocitrate Dehydrogenase 1 (NADP+), Soluble
Entrez ID:
Related biomarkers:
IDH1 mutation
Cholangiocarcinoma
ivosidenib
Sensitive: A1 - Approval
IDH1 mutation
AML
ivosidenib
Sensitive: A1 - Approval
IDH1 mutation
AML
venetoclax
Sensitive: A2 - Guideline
IDH1 mutation
Sarcoma
ivosidenib
Sensitive: A2 - Guideline
IDH1 mutation
Glioma
temozolomide gel
Sensitive: B - Late Trials
IDH1 mutation
AML
gilteritinib
Resistant: B - Late Trials
IDH1 mutation
Glioma
temozolomide
Sensitive: B - Late Trials
IDH1 mutation
Glioma
PCV
Sensitive: B - Late Trials
IDH1 mutation
AML
venetoclax + azacitidine
Sensitive: B - Late Trials
IDH1 mutation
Glioma
ivosidenib
Sensitive: C1 - Off-label
IDH1 mutation
Astrocytoma
temozolomide
Sensitive: C2 – Inclusion Criteria
IDH1 mutation
GBM
temozolomide
Sensitive: C2 – Inclusion Criteria
IDH1 mutation
Glioma
AG-881
Sensitive: C2 – Inclusion Criteria
IDH1 mutation
Cholangiocarcinoma
metformin
Sensitive: C2 – Inclusion Criteria
IDH1 mutation
Sarcoma
metformin
Sensitive: C2 – Inclusion Criteria
IDH1 mutation
Glioma
metformin
Sensitive: C2 – Inclusion Criteria
IDH1 mutation
Glioma
TG02
Sensitive: C3 – Early Trials
IDH1 mutation
AML
cytarabine/daunorubicin liposomal formulation
Sensitive: C3 – Early Trials
IDH1 mutation
AML
venetoclax + ABBV-621
Sensitive: C3 – Early Trials
IDH1 mutation
AML
venetoclax + ivosidenib
Sensitive: C3 – Early Trials
IDH1 mutation
AML
FT-2102
Sensitive: C3 – Early Trials
IDH1 mutation
GBM
pembrolizumab
Resistant: C3 – Early Trials
IDH1 mutation
AML
CFI-400945
Sensitive: C3 – Early Trials
IDH1 mutation
AML
venetoclax + midostaurin
Resistant: C3 – Early Trials
IDH1 mutation
AML
venetoclax + gilteritinib
Resistant: C3 – Early Trials
IDH1 mutation
AML
venetoclax + sorafenib
Resistant: C3 – Early Trials
IDH1 mutation
CMML
venetoclax
Sensitive: C3 – Early Trials
IDH1 mutation
Glioma
BAY1436032
Sensitive: C3 – Early Trials
IDH1 mutation
Anaplastic Astrocytoma
PCV
Sensitive: C3 – Early Trials
IDH1 mutation
GBM
NEO100
Sensitive: C3 – Early Trials
IDH1 mutation
Sarcoma
olaparib
Sensitive: C3 – Early Trials
IDH1 mutation
MDS
venetoclax + ivosidenib
Sensitive: C3 – Early Trials
IDH1 mutation
AML
MEN-1703
Sensitive: C3 – Early Trials
IDH1 mutation
Biliary Tract Cancer
dasatinib
Sensitive: C3 – Early Trials
IDH1 mutation
AML
CDIAG
Sensitive: C3 – Early Trials
IDH1 mutation
AML
ABBV-744
Sensitive: D – Preclinical
IDH1 mutation
AML
venetoclax + IACS-010759
Sensitive: D – Preclinical
IDH1 mutation
GBM
MTX110
Sensitive: D – Preclinical
IDH1 mutation
Glioma
pamiparib
Sensitive: D – Preclinical
IDH1 mutation
Cholangiocarcinoma
AZD0530
Sensitive: D – Preclinical
IDH1 mutation
Cholangiocarcinoma
bosutinib
Sensitive: D – Preclinical
IDH1 mutation
Cholangiocarcinoma
ponatinib
Sensitive: D – Preclinical
IDH1 mutation
Cholangiocarcinoma
dasatinib
Sensitive: D – Preclinical
IDH1 mutation
Glioma
APO866
Sensitive: D – Preclinical
IDH1 mutation
Leukemia
venetoclax
Sensitive: D – Preclinical
IDH1 mutation
Glioma
cetuximab
Resistant: D – Preclinical
IDH1 mutation
Glioma
sunitinib
Sensitive: D – Preclinical
IDH1 mutation
Glioma
bevacizumab
Sensitive: D – Preclinical
IDH1 mutation
Glioma
panobinostat
Sensitive: D – Preclinical
IDH1 mutation
Glioma
NPI-0052
Sensitive: D – Preclinical
IDH1 mutation
Glioma
omacetaxine mepesuccinate
Sensitive: D – Preclinical
IDH1 mutation
Glioma
regorafenib
Sensitive: D – Preclinical
IDH1 mutation
Glioma
dactinomycin
Sensitive: D – Preclinical
IDH1 mutation
Glioma
romidepsin
Sensitive: D – Preclinical
IDH1 mutation
Glioma
daunorubicin
Sensitive: D – Preclinical
IDH1 mutation
Glioma
teniposide
Sensitive: D – Preclinical
IDH1 mutation
Glioma
gemcitabine
Sensitive: D – Preclinical
IDH1 mutation
Glioma
paclitaxel
Sensitive: D – Preclinical